logo-loader
viewAphria

Aphria widens reach in Argentina after striking deal with authorities in province of Jujuy

Aphria’s subsidiary ABP will establish a facility in the Argentine province of Jujuy for the cultivation and processing of cannabis

map of Argentina
As the legislation in Argentina evolves, Aphria will be in a position to scale its production in Jujuy

Aphria Inc (NYSE:APHA), the Canadian cannabis company, is set to expand its cultivation operations in Argentina to the province of Jujuy after signing a letter of intent with the Argentinian state-owned Cannabis Avatãra Sociedad del Estado (CANNAVA) that strikes a cooperation agreement there.

Under the deal’s terms, Aphria’s subsidiary ABP will establish a facility in Jujuy for the cultivation and processing of cannabis as well as for the manufacturing of cannabis derivative products, including cannabis oil.

READ: Aphria and Rapid Dose Therapeutics team up to take on the German cannabis market

The details of the financial terms haven’t been disclosed.

"Aphria is strategically positioned to be among the first companies to produce locally, and eventually commercialize its products in Argentina at much lower cost," said Gabriel Meneses, vice-president for Latin America and Caribbean with Aphria. "We are proud of the relationship we have built with the Province of Jujuy after months of discussions and planning, and thankful for their support."

READ: Aphria reports higher 1Q fiscal first quarter revenue and looks ahead to cannabis legalization in Canada

CANNAVA was established by the Argentine government to advance the cultivation and industrialization of cannabis sativa for medical and scientific use.

As the legislation in Argentina evolves, Aphria will be in a position to scale its production in Jujuy and offer greater access there to medicinal cannabis.

Aphria shares popped by 3.7% to hit $5.60 before the opening bell on Thursday.

Contact Ellen Kelleher at [email protected]

Quick facts: Aphria

Price: 5.66 CAD

TSX:APHA
Market: TSX
Market Cap: $1.51 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

3 hours, 12 minutes ago

2 min read